Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for ...

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.

Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile VANCOUVER, British Columbia, March 25, 2025 (GLOBE ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...

BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...

Professor Janice Walshe, a medical oncologist, explains how the diagnosis process works when it comes to breast cancer, as ...